Stock Price & Analysis

The S1 support level for CING Stock is $4 ,The R1 resistant level for CING Stock is $4.5.

As of the end of day on 2025-02-28, the price of CING Stock was $4.12.

The target price for CING Stock according to analyst rating is 13.33, with the highest price target at 20.00 and the lowest at 8.00. Analysts have a Strong Buy rating on CING Stock overall.

The market cap of CING is $13.2M.

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improve the lives of patients suffering from a multitude of commonly diagnosed conditions. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).

CING has a total of 13 employees.